[1] CRUZ-JENTOFT A J, BAHAT G, BAUER J, et al. Sarcopenia: revised European consensus on definition and diagnosis [J]. Age Ageing, 2019, 48(1):16-31. [2] 薛刚, 吴永华, 王敏红, 等. 老年慢性心力衰竭病人并发肌少症的相关因素分析[J]. 实用老年学杂志, 2020, 34(12):1266-1269. [3] JOSIAK K, JANKOWSKAE A, PIEPOLI M F, et al. Skeletal myopathy in patients with chronic heart failure: Signifificance of anabolic-androgenic hormones [J]. Cachexia Sarcopenia Muscle, 2014, 5(4): 287-296. [4] DELAFONTAINE P, YOSHIDA T. The renin-angiotensin system and the biology of skeletal muscle: mechanisms of muscle wasting in chronic disease states [J]. Trans Am Clin Climatol Assoc, 2016, 127:245-258. [5] ANTINOZZI C, MARAMPON F, CORINALDESI C, et al. Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells [J]. J Endocrinol Invest, 2017, 40(10):1133-1143. [6] MÜLLERT D, NOGUEIRAS R, ANDERMANN M L, et al. Ghrelin [J]. Mol Metab, 2015, 4(6):437-460. [7] RONG Y D, BIAN A L, HU H Y. Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10[J]. BMC Geriatr, 2018, 18(1):308. [8] LIGUORI I, RUSSO G, CURCIO F, et al. Oxidative stress, aging, and diseases [J]. Clin Interv Aging, 2018, 26(13):757-772. [9] HU J, CHENG P, HUANG G Y, et al. Effects of Xin-Ji-Er-Kang on heart failure induced by myocardial infarction: role of inflammation, oxidative stress and endothelial dysfunction [J]. Phytomedicine, 2018, 42:245-257. [10] SAITOH M, ISHIDA J, DOEHNER W, et al. Sarcopenia, cachexia, and muscle performance in heart failure review update 2016 [J]. Int J Cardiol, 2017, 238:5-11. [11] SAKUMA K, AOI W, YAMAGUCHI A. Molecular mechanism of sarcopenia and cachexia: recent research advances [J]. Pflugers Arch, 2017, 469(5/6):573-591. [12] GHOSH R, PATTISON J S. Macroautophagy and chaperone-mediated autophagy in heart failure: the known and the unknown [J]. Oxid Med Cell Longev, 2018, 2018:8602041. [13] TOWER J. Programmed cell death in aging[J]. Ageing Res Rev, 2015, 23(Pt A):90-100. [14] PHILIPPOU A, XANTHIS D, CHRYSSANTHOPΟULOS C, et al. Heart failure-induced skeletal muscle wasting [J]. Current Heart Failure Reports, 2020, 17(5):299-308. [15] ILHAN B, BAHAT G, ERDOGAN C, et al. Anorexia is independently associated with decreased muscle mass and strength in community dwelling older adults [J]. Health Aging, 2019, 23(2):202-206. [16] 周晓宁, 许金海, 王国栋, 等. 肌少症治疗[J]. 中华骨质疏松和骨矿盐疾病杂志, 2020, 13(3):272-279. [17] COKER R H, HAYS N P, WILLIAMS R H, et al. Bed rest worsens impairments in fat and glucose metabolism in older, overweight adults [J]. J Gerontol A Biol Sci Med Sci, 2014, 69(3):363-370. [18] MAHMASSANI Z S, REIDY P T, MCKENZIE A I, et al. Age-dependent skeletal muscle transcriptome response to bed rest-induced atrophy[J]. J Appl Physiol, 2019, 126(4):894-902. [19] NIEMEIJER V M, SNIJDERS T, VERDIJK L B, et al. Skeletal muscle fiber characteristics in patients with chronic heart failure: impact of disease severity and relation with muscle oxygenation during exercise[J]. J Appl Physiol, 2018.DOI: 10.1152/japplphysiol. 00057.2018. [20] DOS SANTOSM R, SAITOH M, EBNER N, et al. Sarcopenia and endothelial function in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating HF (SICA-HF) [J]. Am Med Dir Assoc, 2017, 18(3):240-245. [21] ZHOUL S, XUL J, WANG X Q, et al. Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects: a systematic review and meta-analysis [J]. Drugs Aging, 2015, 32(9):727-735. [22] BAND M M, SUMUKADAS D, STRUTHERS A D. Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial [J]. Trials, 2018, 19(1):6. [23] LAINSCAK M, KEBER I, ANKERS D. Body composition changes in patients with systolic heart failure treated with beta blockers: A pilot study [J]. Int J Cardiol, 2006, 106(3): 319-322. [24] CVAN TROBEC K, GRABNAR I, KEREC KOS M. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study[J]. Eur J Clin Pharmacol, 2016, 72(7):813-822. [25] BURTON L A, MCMURDO M E, STRUTHERS A D, et al. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? [J]. Clin Endocrinol: Oxf, 2011, 75(6):725-729. [26] ARRIETA H, HERVÁS G, REZOLA-PARDO C. Serum myostatin levels are higher in fitter, more active, and non-frail long-term nursing home residents and increase after a physical exercise Intervention [J]. Gerontology, 2019, 65(3):229-239. [27] FERNHALL B. Long-term aerobic exercise maintains peak VO(2), improves quality of life, and reduces hospitalisations and mortality in patients with heart failure [J]. J Physiother, 2013, 59(1):56. [28] EBNER N, VON HAEHLING S. Cachexia and sarcopenia in chronic heart failure: change in muscle strength and muscle structure [J]. Internist: Berl, 2018, 59(5):439-444. [29] DUPONT J, DEDEYNE L, DALLE S, et al. The role of omega-3 in the prevention and treatment of sarcopenia [J]. Aging Clin Exp Res, 2019, 31(6):825-836. [30] D'AMORE C, MARSICO F, PARENTE A, et al. Vitamin D deficiency and clinical outcome in patients with chronic heart failure [J]. Nutr Metab Cardiovasc Dis, 2017, 27(10):837-849. |